Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination

Autor: Yu HH, Yonemura Y, Hsieh MC, Lu CY, Wu SY, Shan YS

Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 15, Pp 129-136 (2019)

Hsin-Hsien Yu,1,2 Yutaka Yonemura,3,4 Mao-Chih Hsieh,2,5 Chang-Yun Lu,2 Szu-Yuan Wu,6,7 Yan-Shen Shan1,8 1Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 2Division of General Surgery, Department of

Externí odkaz: https://doaj.org/article/f2572f951116413686808a8401fb8064

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

Autor: Tempero, Margaret, Ko, Andrew, Ko, AH, Shan, YS, Su, WC, Lin, YL, Dito, E, Ong, A, Wang, YW, Yeh, CG, Chen, LT

Publikováno v: Tempero, Margaret; Ko, Andrew; Ko, AH; Shan, YS; Su, WC; Lin, YL; et al.(2013). A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/5937t6f3

Background: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ae8c5607a9b259c5de54f0100e6801c2
http://www.escholarship.org/uc/item/5937t6f3

A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer

Autor: E. Dito, Anna Ong, Li-Tzong Chen, Shan Ys, Wu Chou Su, G. Yeh, Andrew H. Ko, M. A. Tempero, Yu-Lin Lin

Publikováno v: Journal of Clinical Oncology. 29:237-237

237 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved pharmacokinetics and tumor biodistribution of both CPT-11 and its active metabolite-SN38 compared to the free form drug. PEP02 has showed enco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e53bcae5bdffb4a571f43cafd20d3c4a
https://doi.org/10.1200/jco.2011.29.4_suppl.237

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.